MX2021000312A - Pharmaceutical composition containing a peptide. - Google Patents

Pharmaceutical composition containing a peptide.

Info

Publication number
MX2021000312A
MX2021000312A MX2021000312A MX2021000312A MX2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
peptide
composition containing
composition
linaclotide
Prior art date
Application number
MX2021000312A
Other languages
Spanish (es)
Inventor
George Shlieout
Christopher Rupp
Ronny Schulze
Den Akker Rob Van
Kuldeep Bhokare
Jörn Lüders
Jörg Hagedorn
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of MX2021000312A publication Critical patent/MX2021000312A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a stable pharmaceutical composition for oral administration comprising Linaclotide or its pharmaceutically acceptable salts and a carrier. Methods of preparing and using the composition are also provided. In particular, the composition may be used in the treatment of gastrointestinal disorders, such as chronic constipation and irritable bowel syndrome.
MX2021000312A 2018-07-09 2019-07-08 Pharmaceutical composition containing a peptide. MX2021000312A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811025533 2018-07-09
PCT/IB2019/000716 WO2020012243A2 (en) 2018-07-09 2019-07-08 Pharmaceutical composition containing a peptide

Publications (1)

Publication Number Publication Date
MX2021000312A true MX2021000312A (en) 2021-06-08

Family

ID=68165587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000312A MX2021000312A (en) 2018-07-09 2019-07-08 Pharmaceutical composition containing a peptide.

Country Status (6)

Country Link
AR (1) AR115724A1 (en)
BR (1) BR112021000201A2 (en)
CL (1) CL2021000022A1 (en)
CO (1) CO2021000158A2 (en)
MX (1) MX2021000312A (en)
WO (1) WO2020012243A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033427A1 (en) 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
BRPI0917807A2 (en) 2008-08-15 2019-11-19 Forest Laboratories Holdings Ltd stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016521249A (en) 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド Linaclotide composition
US10272131B2 (en) 2014-08-11 2019-04-30 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
US10507204B2 (en) * 2014-12-19 2019-12-17 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide

Also Published As

Publication number Publication date
WO2020012243A2 (en) 2020-01-16
WO2020012243A3 (en) 2020-03-05
BR112021000201A2 (en) 2021-08-10
CO2021000158A2 (en) 2021-01-18
AR115724A1 (en) 2021-02-17
CL2021000022A1 (en) 2021-07-19

Similar Documents

Publication Publication Date Title
MY187047A (en) Selective pyy compounds and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
RS52831B (en) Buprenorrphine wafer for drug substitution therapy
MX2019001322A (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof.
IN2013MU03583A (en)
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
MX2021004883A (en) Methods and compositions for treating sleep apnea.
MX2018000084A (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin.
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
EA201792237A1 (en) PHARMACEUTICAL COMPOSITIONS
MX2022004739A (en) Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same.
MX2021000312A (en) Pharmaceutical composition containing a peptide.
PH12017501736A1 (en) Indole derivatives
MX2018005345A (en) Pharmaceutical compositions of dimethyl fumarate.
MX2022004014A (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxoh exanoate for intravenous administration and the use thereof.
ZA202200330B (en) Pharmaceutical composition of imatinib
WO2019151966A3 (en) Pharmaceutical tablet compositions of dabigatran
MX2017014725A (en) Dropropizine in combination with ambroxol in the dosage form of syrup or tablets.